AI-assisted, human-published
10/16/2025 /Funding Events
BridGene Biosciences Concludes $28M Series B+ Funding Round Led by Bayland Capital
Bayland Capital leads the $28 million Series B+ financing round for BridGene Biosciences, earmarked for advancing BGC-515 and accelerating programs in oncology and autoimmune diseases.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com